Company / Operating Margin
Esperion Therapeutics, Inc. Operating Margin History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
14.9%
FY2025
5-year range
-289.0% / 16.4%
FY2021-FY2025
Trend
-8.7%
vs FY2024
Sector context
#32 of 136
Health Care
What the data says
Esperion Therapeutics, Inc.'s operating margin of 14.9% is higher than 76% of companies in the Health Care sector (FY2025). Operating Margin has fluctuated over the past 7 years, ranging from -289.0% in FY2021 to 16.4% in FY2024.
Based on SEC 10-K filings.
14.9% in FY2025 with a 5-year CAGR of +68.3%. Top quartile in the Health Care sector.
Improved from -133.7% to 14.9% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +252.8pp
- 5-Year Change
- +68.3pp
- 10-Year Change
- -
Sector benchmark
+101.9% above sector average
Key checks
Key Insights
- In FY2025, operating margin decreased 8.7% year-over-year.
- Currently 793.9pp above the Health Care sector average.
- Peak operating margin was recorded in FY2024.
- Lowest operating margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 14.9% | -8.7% |
| FY2024 | 16.4% | +112.2% |
| FY2023 | -133.7% | +43.8% |
| FY2022 | -237.8% | +17.7% |
| FY2021 | -289.0% | -441.7% |
| FY2020 | -53.3% | +15.0% |
| FY2019 | -62.7% | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026